Merck Finalizes $6 Billion Debt Offering to Repay Terns Acquisition Loan

summarizeSummary

Merck completed a $6 billion debt offering to refinance the acquisition of Terns Pharmaceuticals, securing long-term funding for the strategic transaction.

check_boxKey Events

• Debt Offering Finalized

  Merck & Co., Inc. completed a public offering of $6.0 billion in senior unsecured notes, including $500 million in floating rate notes due 2028 and $5.5 billion in fixed-rate notes with maturities from 2028 to 2056 and interest rates ranging from 4.300% to 5.850%.

• Refinancing Acquisition Debt

  The net proceeds of approximately $5.96 billion from this offering will be used to repay in full outstanding borrowings under a 364-Day Delayed Draw Term Loan Credit Agreement, which was incurred to finance a portion of the Terns Pharmaceuticals acquisition.

• Terns Acquisition Context

  The Terns Pharmaceuticals acquisition, valued at approximately $6.7 billion, closed on May 5, 2026, and is intended to diversify and strengthen Merck's oncology position.

auto_awesomeAnalysis

Merck has finalized a substantial $6 billion debt offering, consisting of both floating and fixed-rate notes with maturities ranging from 2028 to 2056. The proceeds are specifically earmarked to repay outstanding borrowings from a 364-day term loan, which was used to finance a portion of the recently closed Terns Pharmaceuticals acquisition. This move formalizes the long-term financing for a strategic acquisition, a standard corporate finance practice for a company of Merck's size.